Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 10/20 | 0.59 |
| ▸ | LMNA | P02545 | 7/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bamifylline SCHEMBL637064 | 0.99 | RXFP1 (0.58) | RXFP1TSHRLMNANPSR1HTT | |
| Bamifylline SCHEMBL1648640 | 0.98 | RXFP1 (0.57) | RXFP1TSHRLMNANPSR1HTT | |
| Bamifylline SCHEMBL27460692 | 0.94 | RXFP1 (0.53) | RXFP1TSHRLMNANPSR1HTT | |
| SCHEMBL684310 | 0.93 | RXFP1 (0.66) | RXFP1TSHRLMNANPSR1HTT | |
| Bamifylline SCHEMBL28086377 | 0.92 | TSHR (0.53) | RXFP1TSHRLMNANPSR1HTT | |
| SCHEMBL19829270 | 0.92 | TSHR (0.64) | RXFP1TSHRLMNANPSR1HTT | |
| Bamifylline SCHEMBL28086311 | 0.85 | TSHR (0.44) | RXFP1TSHRLMNANPSR1HTT | |
| Bamifylline SCHEMBL20522800 | 0.85 | USP2 (0.46) | RXFP1TSHRLMNANPSR1HTT | |
| SCHEMBL1334308 | 0.84 | ADORA1 (0.57) | TSHRLMNANPSR1HTTSMN1; SMN2 | |
| SCHEMBL1334833 | 0.81 | ADORA1 (0.53) | TSHRLMNANPSR1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1442 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| US-11534375-B2 | Solvent-free method of encapsulating a hydrophobic active | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-27 | — | — | US | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| US-11124835-B2 | Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers | Transgenion—International Institute for Regenerative Translational Medicine GmbH (AT) | 2021-09-21 | — | — | US | claimed |
| EP-0480934-B1 | A SLIMMING PHARMACEUTICAL COMPOSITION | NYCOMED DAK AS (DK) | 1994-06-29 | — | — | EP | claimed |
| EP-0324981-B1 | NEW GALENIC FORMULATIONS WITH PROGRAMMED RELEASE | ALFA WASSERMANN S.p.A. (IT) | 1993-03-10 | — | — | EP | claimed |
| EP-0270305-B1 | SPHEROIDS | Euroceltique S.A. (LU) | 1993-01-20 | — | — | EP | claimed |
| EP-0480934-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION. | DAK LAB AS (DK) | 1992-04-22 | — | — | EP | claimed |
| US-5091189-A | Tablet contains 3-alkylxanthine, hydrophilic or hydrophobic polymers, and wax from the group consists of polyalkylene glycol | EUROCELTIQUE S.A. (LU) | 1992-02-25 | — | — | US | claimed |
| US-5043167-A | Galenic formulations with programmed release | ALFA WASSERMANN S.P.A. (IT) | 1991-08-27 | — | — | US | claimed |
| WO-1991000730-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION | DAK-LABORATORIET A/S (DK) | 1991-01-24 | — | — | WO | claimed |
| EP-0324981-A1 | New galenic formulations with programmed release | ALFA WASSERMANN S.p.A. (IT) | 1989-07-26 | — | — | EP | claimed |
| US-4844910-A | CONTROLLED RELEASE OF THEOPHYLLINE DERIVATIVES | EUROCELTIQUE, S.A. (LU) | 1989-07-04 | — | — | US | claimed |
| EP-0270305-A2 | Spheroids | Euroceltique S.A. (LU) | 1988-06-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | RXFP1 757/4885TSHR 2692/4885LMNA 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.